Capital Fund Management (CFM)’s Edwards Lifesciences EW Stock Holding History

Capital Fund Management (CFM)’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.43M	Buy	30,300 +17,900	+144%	+$1.48M	0.01%	1266
2025 Q4	$1.06M	Sell	12,400 -26,500	-68%	-$2.17M	﹤0.01%	1999
2025 Q3	$3.03M	Buy	+38,900	New	+$3.04M	0.01%	1562
2025 Q1	–	Sell	-30,700	Closed	-$2.27M	–	2105
2024 Q4	$2.27M	Sell	30,700 -2,500	-8%	-$175K	0.01%	1435
2024 Q3	$2.19M	Sell	33,200 -3,700	-10%	-$269K	0.01%	1390
2024 Q2	$3.41M	Sell	36,900 -370,700	-91%	-$32.8M	0.01%	1142
2024 Q1	$39M	Sell	407,600 -146,500	-26%	-$12.3M	0.11%	244
2023 Q4	$42.3M	Buy	554,100 +410,900	+287%	+$28.6M	0.11%	250
2023 Q3	$9.92M	Buy	143,200 +113,600	+384%	+$9.13M	0.03%	622
2023 Q2	$2.79M	Sell	29,600 -46,900	-61%	-$4.08M	0.01%	1076
2023 Q1	$6.33M	Buy	76,500 +48,200	+170%	+$3.79M	0.03%	654
2022 Q4	$2.11M	Buy	+28,300	New	+$2.18M	0.01%	919
2022 Q3	–	Sell	-23,200	Closed	-$2.21M	–	1489
2022 Q2	$2.21M	Buy	+23,200	New	+$2.4M	0.02%	787
2022 Q1	–	Sell	-30,700	Closed	-$3.98M	–	1539
2021 Q4	$3.98M	Sell	30,700 -4,400	-13%	-$513K	0.03%	728
2021 Q3	$3.97M	Buy	+35,100	New	+$4.01M	0.03%	664
2021 Q1	–	Sell	-10,800	Closed	-$985K	–	1370
2020 Q4	$985K	Sell	10,800 -21,700	-67%	-$1.8M	0.01%	995
2020 Q3	$2.59M	Buy	32,500 +6,700	+26%	+$523K	0.03%	561
2020 Q2	$1.78M	Buy	25,800 +17,700	+219%	+$1.26M	0.03%	535
2020 Q1	$509K	Sell	8,100 -115,200	-93%	-$8.31M	0.01%	1022
2019 Q4	$9.59M	Buy	123,300 +68,100	+123%	+$5.32M	0.08%	349
2019 Q3	$4.05M	Sell	55,200 -42,900	-44%	-$3.01M	0.04%	545
2019 Q2	$6.04M	Buy	98,100 +84,000	+596%	+$5.08M	0.06%	445
2019 Q1	$899K	Buy	+14,100	New	+$805K	0.01%	1063
2018 Q3	–	Sell	-87,000	Closed	-$4.22M	–	2043
2018 Q2	$4.22M	Sell	87,000 -900	-1%	-$42K	0.02%	801
2018 Q1	$4.09M	Buy	87,900 +72,600	+475%	+$3.15M	0.02%	760
2017 Q4	$575K	Sell	15,300 -300	-2%	-$11K	﹤0.01%	1407
2017 Q3	$568K	Sell	15,600 -25,500	-62%	-$973K	﹤0.01%	1148
2017 Q2	$1.62M	Buy	41,100 +29,400	+251%	+$1.07M	0.01%	771
2017 Q1	$367K	Sell	11,700 -5,100	-30%	-$160K	﹤0.01%	1235
2016 Q4	$525K	Sell	16,800 -600	-3%	-$19.4K	﹤0.01%	1246
2016 Q3	$699K	Buy	+17,400	New	+$655K	0.01%	1081
2015 Q3	–	Sell	-27,000	Closed	-$641K	–	1481
2015 Q2	$641K	Sell	27,000 -12,000	-31%	-$271K	0.01%	987
2015 Q1	$926K	Buy	39,000 +24,000	+160%	+$538K	0.01%	812
2014 Q4	$318K	Buy	+15,000	New	+$301K	﹤0.01%	1314
2014 Q1	–	Sell	-46,200	Closed	-$506K	–	1770
2013 Q4	$506K	Sell	46,200 -112,200	-71%	-$1.26M	0.01%	1247
2013 Q3	$1.84M	Buy	+158,400	New	+$1.85M	0.03%	676

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Fund Management (CFM)'s EW Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 16,061 shares — an estimated $1.32M sold.

Capital Fund Management (CFM) first reported a position in EW in Q1 2014 and held it in 34 quarters. The position peaked at $49M in Q4 2015. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Capital Fund Management (CFM) reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Capital Fund Management (CFM) sold 16,061 Edwards Lifesciences shares in Q1 2026, an estimated $1.32M.
Capital Fund Management (CFM) first reported a position in Edwards Lifesciences in Q1 2014 and held it in 34 quarters.
Capital Fund Management (CFM)'s Edwards Lifesciences position peaked at $49M in Q4 2015.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.